Darnisha Grant Harrison is the President & CEO of Ennaid Therapeutics, a development-stage biopharmaceutical company. As the company’s Head, she is responsible for guiding the company to its intention of being first-to-market with the world’s first therapeutic cure for two of the most notorious mosquito-borne diseases in the world, Zika virus and dengue virus.
There are a total of eleven drugs in the company’s pipeline. Darnisha is also the founder of MBRF, a not-for-profit 501 c(3) organization whose mission is to, Cure The Bite of a mosquito.
Once a Microbiologist and Chemist, Darnisha is now a nationally recognized pharmaceutical entrepreneur by Newsweek Magazine and has greater than twenty-four years’ experience in the Life Sciences.
Prior to founding Ennaid Therapeutics, she spent three years as a scientist, most notably at Amgen and the University of Georgia, and sixteen years in Business Development/Licensing as a Director in various companies within the pharmaceutical research & development industry.
She is an accomplished negotiator and deal-maker in identifying, negotiating and closing drug development deals and strategic collaborations. Darnisha is accomplished in technology acquisition and licensing, strategic business development, business planning and brisk, successful execution of such plans. A member of the American Association for the Advancement of Science, the New York Academy of Sciences, The World Chamber of Commerce and Women In BIO, Darnisha received a B.S. in Microbiology and Minor in Chemistry from LSU.
William J. Brock is the Principal of Brock Scientific Consulting, LLC. He has about 30 years of experience as a toxicologist, manager and consultant for research and development in the pharmaceutical, consumer product, food, medical device and chemical industries. Experienced in occupational and industrial toxicology; nonclinical safety program study design, conduct, interpretation and reporting; evaluating clinical and product safety data; in training and managing staff; dealing with a wide range of U.S. and foreign regulatory bodies, commercial concerns, and contract research organizations; labeling and other regulatory compliance issues; writing reports, regulatory and toxicology position papers; presentations to regulatory authorities; risk and safety assessments and litigation support. He attended University of Kentucky in Lexington, Kentucky (1980-1983) and earned a Ph.D. in Toxicology.
Michael has 20 years experience in the Medical Diagnostic and Pharmaceutical industries. Qualifications include a broad range of experiences in pharmaceutical sales, sales training, representative development, sales management as well as medical diagnostic distribution. Having served as a Pharmaceutical Sales Trainer / Manager, Michael has assisted in the commercial launch of several blockbuster pharmaceutical products. He brings the experience of a stellar award winning sales track record having won multiple sales awards in the pharmaceutical and medical diagnostic industries. Michael received his Bachelor of Science degree in Chemistry from Tennessee State University and is currently completing his MBA in conjunction with a Six Sigma Lean Green Belt certification from Indiana University, School of Business and Economics Northwest Campus.
Jason is a corporate finance professional with nearly 20 years’ experience working with health care and biopharmaceutical companies. He began a career on Wall Street in 1995 and later spent 13 years in London where he had a chance to work with companies from around the world. His specializes in licensing and M&A, capital raising and strategic budgeting and planning. He returned to his hometown of Atlanta in 2013, and now works as an independent consultant, assisting a number of local companies in matters of strategic finance. Mr. Foss is a graduate of Georgetown University (BA – Psychology) and the University of Chicago (MBA – Finance and Accounting).
Scientific Officer, Inventor, & Scientific Advisory Board
Dr. Garry is the inventor of Ennaid Therapeutics’ technology and is a world-renowned Microbiologist and Virologist. Research in his laboratory focuses on a number of breakthrough discoveries in viral pathogenesis and has resulted in the development of many antiviral peptide drugs. He is currently managing programs to develop therapies/vaccines for dengue virus and lassa virus. He is the founding Editor-In-Chief of Virology Journal and has served on many NIH review panels. Dr. Garry received a Ph.D. in Microbiology and Virology from the University of Texas, Austin.
Key Opinion Leader
Dr. Corey Hebert is one of the most illustrious physicians practicing medicine in the United States today. His travels across the country and around the globe have connected him to thousands of people as both a healer and a motivator, all the while practicing both Pediatrics and Emergency Medicine. He is a Professor at both LSU Health Sciences Center and Tulane University Medical Center and has been the Principal Investigator on over 50 phase 2 and 3 clinical trials on various pharmacotherepeutic agents. Dr. Hebert is one of the most sought after speakers in his field. He is a highly regarded medical broadcast journalist, working as on-air Chief Medical Editor for the NBC television affiliate in New Orleans, Louisiana and the Gulf Coast for over a decade. He is a frequent on-air contributor to the “Dr. Oz Show”, the Discovery Channel’s “How Stuff Works” television show and he has made hundreds of appearances on national television networks and outlets such as CNN, CBS, National Geographic, the Meredith Vieira Show, Good Morning America and the Today Show. Recognized as an expert on health policy and legislation, Dr. Hebert is also a nationally recognized consultant to international healthcare organizations such Novartis Pharmaceuticals and Rhodes Pharma which rely on his expertise in the medical landscape before any decisions are made. Dr. Hebert is the Chief Executive Officer of Community Health TV which is the parent company of BlackhealthTV.com and LatinohealthTV.com. Dr. Hebert has recently accepted the role of Chief Medical Advisor to the NBA Retired Players Association and he is attributed to saving many lives of our retired superstars of basketball. Dr. Hebert is 46 years old and has one son, Corey Joseph Hebert, Jr. and one daughter, Elan Jolie Hebert.
VP of Pharmaceutical Sciences Consultant/CMC Development, & Scientific Advisory Board
With greater than thirty years of experience in the pharmaceutical and related industries, Dr. Moreton is currently the V.P. of Pharmaceutical Sciences at FinnBrit Consulting. Dr. Moreton spent the bulk of his career at Penwest Pharmaceuticals and Idenix Pharmaceuticals, where he served as VP of Pharmaceutical Sciences. His extensive expertise in the pharmaceutical industry is in preformulation, formulation and process design and development, scale-up and clinical manufacture, technical transfer to commercial manufacture, process validation, analytical method development and validation, quality assurance, excipients, GMPs for excipients, pharmaceutical finished products, nutritional products and APIs, CMC regulatory documentation, contract manufacturing and development and packaging. Dr. Moreton’s additional specialties include pharmaceutical product development, clinical manufacture, project coordination and mangement, technical transfer, CGMP and scale-up. He received a Ph.D. in Pharmaceutics from Cardiff University/Prifysgol Caerdydd.
Inventor & Scientific Advisory Board
Dr. Michael is a co-inventor of Ennaid Therapeutics’ dengue peptide technology. His previous accomplishments include major discoveries on HIV protease inhibitor resistance and the origin of HIV-1 from chimpanzees. His current research interests are directed towards the development of anti-virals and vaccines against dengue virus. He serves on the editorial boards of Virology Journal and PLOS Neglected Tropical Diseases. Dr. Michael received a Ph.D. in Chemistry from the Johns Hopkins University.
Sr. Process Engineer, Manager of Technical & Scientific Affairs, & Scientific Advisory Board
With twenty one years of experience in the pharma industry Romeo is a stellar scientist and has worked in big pharma and small start-up pharma companies. He has held positions at Abbott/now Abbvie, Sciele Pharma & Wockhardt. His expertise is in basic chemistry, tech transfer, process development and optimization, scale-up/down and validation. He has many years of experience managing outsourced development projects. Romeo has a Masters in Chemistry, a Masters in Chemical Engineering and a B.S. in Chemistry from the University of Illinois, Chicago.
Scientific Advisory Board
GARY H.S. STRAUSS is a dedicated medical research scientist with doctoral and post-doctoral training in medical microbiology, immunology, medical genomics, and toxicology. A principal investigator in US and British government laboratories, as well as a research professor at a prominent US medical school, and collaborator with several biotechnology companies, he spent over twenty years conducting original research while also fulfilling requisite mentoring and administrative responsibilities. Lab work took precedence in those years as he developed new methods for measuring drug resistance and other genetically-induced and -determined responses to environmental mutagens/ carcinogens including, in many instances, medical therapies then undergoing ICH- and FDA-supervised clinical trials. In his laboratory years, he also introduced novel methods for use in stem- and differentiated cell cryopreservation and assessing immunocompetency, but he is best known as co-inventor of the seminal technology for detecting, enumerating, and monitoring mutant frequencies among somatic cells arising in-vivo and induced in-vitro. Gary received his PhD in Medical Microbiology from the U. Vermont College of Medicine, Burlington, VT and a DPhil in Genetic Toxicology from U. Sussex Medical Research Council, Brighton, UK.
Dr. Myeni has a background in both business and medicine. In addition to having a history in sales and logistics, she is an ophthalmologist who has completed advanced specialty training in both the medical and surgical management of glaucoma. Dr. Myeni received a Doctor of Medicine degree from the Medical College of Georgia. Thereafter, she acquired a Masters in Public Health from Harvard University, with a concentration in Health Management and she received an undergraduate degree from the Amherst College. She completed her residency training in ophthalmology at Howard University Hospital, after which she acquired a fellowship in glaucoma at Wills Eye Hospital in Philadelphia, PA. Dr. Myeni is currently a practicing Ophthalmologist in Washington, D.C.